|
🐜
|
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
22 auth.
G. Dore,
F. Altice,
A. Litwin,
O. Dalgard,
E. Gane,
O. Shibolet,
A. Luetkemeyer,
R. Nahass,
C. Peng,
B. Conway,
...
J. Grebely,
A. Howe,
I. N. Gendrano,
E. Chen,
Hsueh‐Cheng Huang,
F. Dutko,
D. Nickle,
B. Nguyen,
J. Wahl,
E. Barr,
M. Robertson,
H. Platt
|
8 |
2016 |
8
🐜
|
|
🐜
|
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
26 auth.
M. Manns,
S. Pol,
I. Jacobson,
P. Marcellin,
S. Gordon,
C. Peng,
Ting Chang,
G. Everson,
J. Heo,
G. Gerken,
B. Yoffe,
W. Towner,
M. Bourliere,
S. Metivier,
C. Chu,
...
W. Sievert,
J. Bronowicki,
D. Thabut,
Youn-Jae Lee,
J. Kao,
F. Mcphee,
J. Kopit,
P. Mendez,
Misti Linaberry,
E. Hughes,
S. Noviello
|
8 |
2014 |
8
🐜
|
|
🐜
|
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
18 auth.
P. Kwo,
E. Gane,
C. Peng,
Brian L. Pearlman,
J. Vierling,
L. Serfaty,
M. Buti,
S. Shafran,
P. Stryszak,
Li Lin,
...
J. Gress,
Stuart Black,
F. Dutko,
M. Robertson,
J. Wahl,
L. Lupinacci,
E. Barr,
B. Haber
|
8 |
2017 |
8
🐜
|
|
🐜
|
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study
15 auth.
Y. Liaw,
M. Raptopoulou‐Gigi,
H. Cheinquer,
S. Sarin,
T. Tanwandee,
N. Leung,
C. Peng,
R. Myers,
Robert S. Brown,
L. Jeffers,
...
N. Tsai,
J. Białkowska,
Shijie Tang,
S. Beebe,
E. Cooney
|
7 |
2011 |
7
🐜
|
|
🐜
|
Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial
8 auth.
K. Su,
H. Lai,
Hui‐Ting Yang,
W. Su,
C. Peng,
J. Chang,
...
Hui-Chih Chang,
C. Pariante
|
7 |
2014 |
7
🐜
|
|
🦁
|
Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy.
C. Peng,
R. Chien,
Y. Liaw
|
7 |
2012 |
7
🦁
|
|
🐜
|
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
28 auth.
T. Su,
Tsung‐Hui Hu,
Chi-yi Chen,
Yi‐Hsiang Huang,
W. Chuang,
Chun-Che Lin,
Chia-Chi Wang,
W. Su,
Ming‐Yao Chen,
C. Peng,
R. Chien,
Yi-Wen Huang,
Horng‐Yuan Wang,
Chih‐Lin Lin,
Sheng-Shun Yang,
...
Tsung-Ming Chen,
L. Mo,
Shih-Jer Hsu,
K. Tseng,
T. Hsieh,
F. Suk,
Chi-Tan Hu,
Ming-Jong Bair,
Cheng‐Chao Liang,
Y. Lei,
T. Tseng,
Chi-Ling Chen,
J. Kao
|
7 |
2016 |
7
🐜
|
|
🐜
|
Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
16 auth.
N. Leung,
C. Peng,
H. Hann,
J. Sollano,
Judy Lao-Tan,
Chao-Wei Hsu,
L. Lesmana,
M. Yuen,
L. Jeffers,
M. Sherman,
...
A. Min,
K. Mencarini,
U. Diva,
A. Cross,
R. Wilber,
J. López-Talavera
|
7 |
2009 |
7
🐜
|
|
🐬
|
Phospholipase A2 and Cyclooxygenase 2 Genes Influence the Risk of Interferon-α–Induced Depression by Regulating Polyunsaturated Fatty Acids Levels
K. Su,
Shih-Yi Huang,
C. Peng,
H. Lai,
C. Pariante
|
7 |
2010 |
7
🐬
|
|
🐜
|
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.
18 auth.
Chun-Jen Liu,
Po-Huang Lee,
D. Lin,
Cheng‐Chung Wu,
L. Jeng,
P. Lin,
K. Mok,
Wei-Chen Lee,
H. Yeh,
M. Ho,
...
Sheng-Shun Yang,
C. Lee,
Ming-Chin Yu,
R. Hu,
C. Peng,
Kuan-Lang Lai,
S. Chang,
Pei‐Jer Chen
|
7 |
2009 |
7
🐜
|
|
🐜
|
Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions
26 auth.
W. Tak,
Shi-Ming Lin,
Yijun Wang,
Jia-sheng Zheng,
A. Vecchione,
S. Park,
M. Chen,
S. Wong,
R. Xu,
C. Peng,
Y. Chiou,
G-T Huang,
Jianqiang Cai,
B. J. Abdullah,
June-Sung Lee,
...
Jae Young Lee,
J. Choi,
Juliet Gopez-Cervantes,
M. Sherman,
R. Finn,
Masao Omata,
Michael O’Neal,
L. Makris,
N. Borys,
R. Poon,
R. Lencioni
|
6 |
2017 |
6
🐜
|
